Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof

a biomarker and acute heart failure technology, applied in the field of proteinand/or peptide-based biomarkers, can solve the problems of unambiguous diagnosis, inability of acute heart failure to pump efficiently and where it cannot no longer, and considerable morbidity and mortality among older adults

Inactive Publication Date: 2011-11-10
MYCARTIS
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent text describes a new biomarker called Quiescin Q6 that is useful for predicting, diagnosing, and prognosticating acute heart failure (AHF). The inventors found that patients with AHF have significantly higher levels of Quiescin Q6 compared to patients with other non-AHF conditions and stable heart failure. The Quiescin Q6 marker can be measured in a simple blood sample and is not influenced by other disease parameters such as age, renal failure, or co-morbidities. The method of predicting, diagnosing, and prognosticating AHF involves measuring the quantity of Quiescin Q6 in a sample from the subject and comparing it to a reference value. The invention provides a more accurate and reliable biomarker for predicting and diagnosing AHF than current gold standard biomarkers."

Problems solved by technology

Heart failure is a major public health issue in developed countries and is the cause of considerable morbidity and mortality among older adults.
Acute heart failure (AHF) is a sudden inability of the heart to pump efficiently and where it can no longer foresee the bodily demands for oxygen.
The clinical signs of heart disease and AHF are often non-specific which can make unambiguous diagnosis demanding.
A common symptom of AHF is the shortness of breath (dyspnea or dyspnoea).
However, usually only a fraction of subjects presenting with dyspnea upon admission to a physician or clinic suffer from AHF.
Although BNP is sensitive, its specificity is relatively low, and is especially problematic due to the “grey zone” between 100-400 pg / mL.
Also, BNP levels vary with age, sex, weight and other medical conditions, thereby confounding the diagnosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
  • Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
  • Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

MASSTERMIND Discovery Platform for Discovery of New Biomarkers for AHF

[0333]MASSTERMIND Experimental Setup

[0334]For biomarker discovery, we analysed the changes in protein expression using mass spectrometric detection of protein levels using our previously published COFRADIC™ technology platform (substantially as described inter alia in WO 02 / 077016 and in Gevaert et al. 2003, Nat Biotechnol 21(5): 566-9).

[0335]All plasma samples were depleted for the most abundant proteins using commercially available affinity-based chromatographic columns (e.g. Agilent Technologies). Depletion efficiency of albumin and immunoglobulin G (IgG) was checked using Western Blot analysis. Samples were prepared for MASStermind analysis according to the standard N-terminal COFRADIC procedures. Samples and controls were differentially labelled by trypsin mediated incorporation of 18O / 16O at the C-terminus of every tryptic peptide. After N-terminal peptide sorting, NanoLC separations followed by direct spott...

example 2

MASSterclass Targeted Protein Quantitation for Early Validation of Candidate Markers Derived from Discovery

[0338]MASSTERCLASS Experimental Setup

[0339]MASSterclass assays use targeted tandem mass spectrometry with stable isotope dilution as an end-stage peptide quantitation system (also called Multiple Reaction Monitoring (MRM) and Single Reaction Monitoring (SRM)). The targeted peptide is specific (i.e., proteotypic) for the specific protein of interest. i.e., the amount of peptide measured is directly related to the amount of protein in the original sample. To reach the specificity and sensitivity needed for biomarker quantitation in complex samples, peptide fractionations precede the end-stage quantitation step.

[0340]A suitable MASSTERCLASS assay may include the following steps:[0341]Plasma / serum sample[0342]Depletion of human albumin and IgG (complexity reduction on protein level) using affinity capture with anti-albumin and anti-IgG antibodies using ProteoPrep spin columns (Sigm...

example 3

Unbiased Discovery of Novel AHF Markers Using MASStermind

[0370]The MASStermind proteomic discovery platform was used to discover novel low abundance AHF protein biomarker candidates directly in patient plasma. Serial plasma samples collected prospectively from 10 patients with AHF on admission to the emergency department and just prior to their discharge from hospital were analyzed alongside age and gender matched control samples collected from healthy individuals (FIG. 4). Comparing protein profiles of AHF patients at admission versus at discharge yields biomarker candidates for treatment monitoring and discharge decisions while a comparison of AHF patients with healthy matched controls provides with new biomarker candidates for improving diagnostic accuracy.

[0371]Following the MASStermind procedure differential features that discriminate AHF and healthy populations and / or admission and discharge samples were selected by different statistical measures (SAM and one-rule classifier)....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
pHaaaaaaaaaa
mass spectrometry analysisaaaaaaaaaa
Login to View More

Abstract

The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and / or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and / or performing said methods.

Description

FIELD OF THE INVENTION[0001]The invention relates to protein- and / or peptide-based biomarkers and to agents specifically binding thereto, for use in predicting, diagnosing and / or prognosticating diseases or conditions in subjects. More particularly, the application discloses certain proteins and / or peptides as new biomarkers for acute heart failure; methods for predicting, diagnosing and / or prognosticating acute heart failure based on measuring said biomarker proteins and / or peptides; and kits and devices for measuring said proteins and / or peptides and / or performing said methods.BACKGROUND OF THE INVENTION[0002]In many diseases and conditions, a favourable outcome of prophylactic and / or therapeutic treatments is strongly correlated with early and / or accurate prediction, diagnosis and / or prognosis of the disease or condition. Therefore, there exists a continuous need for additional and preferably improved manners for early and / or accurate prediction, diagnosis and / or prognosis of dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/26G01N33/566G01N33/573H01J49/26C12M1/34C12N9/02C12N9/96C40B30/04C40B40/10
CPCG01N33/558G01N2800/325G01N2333/90212G01N33/6893C12Y108/03002G01N33/54388G01N33/573G01N2560/00G01N2800/52
Inventor KAS, KOEN
Owner MYCARTIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com